Navigation Links
Women Less Likely to Get Heart Defibrillators
Date:10/2/2007

And blacks are less likely to receive the lifesaving devices, studies find

TUESDAY, Oct. 2 (HealthDay News) -- Women are less likely than men to receive implantable defibrillators, and black patients are less likely than white patients to receive the lifesaving heart devices.

Two studies documenting these findings echo previous research, and confirm that little progress has been made in this area of inequity.

"In the mid 1990s, the Institute of Medicine noted that newer technologies and innovative therapies were more likely to be used in men versus women and in whites versus blacks consistently, and recommended that the health-care system needs to figure out how to deliver new therapies more efficiently and equitably," said Dr. Adrian Hernandez, an author of both of the studies, which appear in the Oct. 3 issue of the Journal of the American Medical Association.

"This is a case example where we still haven't done that," added Hernandez, an assistant professor of medicine at the Duke Clinical Research Institute, in Durham, N.C.

"It reconfirms what was found in clinical trials, that the problem still exists," said Dr. Wojciech Zareba, a professor of medicine with the cardiology unit at the University of Rochester (N.Y.) Medical Center. "We do not know the reason for the discrepancy but, in my view, one predominant reason is a lot of education needs to be done among physicians to convince them. People don't know enough and we should have more advertisements during the evening news on sudden cardiac death in women rather than on asthma drugs or breast cancer."

Some 350,000 people in the United States die each year as a result of sudden cardiac death, making it one of the leading causes of death. Although the risk is initially higher in men than in women, that discrepancy disappears after age 85.

Implantable cardioverter-defibrillators (ICDs), introduced about two decades ago, conti
'/>"/>

Copyright©2007 ScoutNews,LLC.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Transdermal HRT not cardioprotective in postmenopausal women with CAD
2. Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease
3. Starvation in pregnant women can cause heart disease to their children
4. Women suffer from sexual dysfunction too
5. Brisk Walking lowers memory loss in women
6. Young womens woes
7. Young womens woes
8. Women find difficulty in calling it Quits
9. FDA approves new device to treat womens bleeding disorder
10. Women recognise faces better
11. Women more susceptible to brain damage from ecstasy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2008)...ibing Service Offered to Over 800 Physicians, DAL...ion (ZixCorp(R)),(Nasdaq: ZIXI ), the leader in ...bing, today announced that L.A. Care, the nation,s...Company,s PocketScript(R) e-Prescribing,Service th...rp is one of,several vendors that will be availabl...
(Date:5/22/2008)... rheumatology experts on Gout Awareness Day to sh...erious condition, NEW YORK, May 22 /PRNewswire/ -...All-Star Maurice Cheeks is partnering with the Gou...the word about gout -- a common,and intensely pain...hree to,five million Americans. The 76ers outperfo...
(Date:5/22/2008)... mission via flexible, secure 4 Gigabit network ...98 percent, PORTLAND, Ore., May 22 /PRNewswire-Fi...TC ), a leading provider of managed voice and data...ced the successful,installation of metro Ethernet ...troenterology and West Side Surgical facilities in...
(Date:5/22/2008)... Milk Mustache Campaign and Everyday Food Team ..., WASHINGTON, May 22 /PRNewswire/ -- America, sta...lk Mustache Campaign and Everyday Food magazine,ar...honor of June Dairy,Month., Whether it,s a sweet ...,smoothie aficionados seeking a taste of fame are ...
Breaking Medicine News(10 mins):Health News:L.A. Care Offers ZixCorp e-Prescribing Services Through Health I.T. Incentive Program 2Health News:L.A. Care Offers ZixCorp e-Prescribing Services Through Health I.T. Incentive Program 3Health News:NBA Coach Maurice Cheeks Teams Up with the Gout & Uric Acid Education Society (GUAES) to Call a 'Time Out for Gout' 2Health News:NBA Coach Maurice Cheeks Teams Up with the Gout & Uric Acid Education Society (GUAES) to Call a 'Time Out for Gout' 3Health News:NBA Coach Maurice Cheeks Teams Up with the Gout & Uric Acid Education Society (GUAES) to Call a 'Time Out for Gout' 4Health News:The Oregon Clinic Extends Patient Care Services Across Metro Portland with Time Warner Telecom's Metro Ethernet Service 2Health News:The Oregon Clinic Extends Patient Care Services Across Metro Portland with Time Warner Telecom's Metro Ethernet Service 3Health News:Thirsting for Healthful Smoothie Recipes That 'got milk?' 2
...ldiers returning from Iraq who have migraine heada...mptoms of post-traumatic stress, depression or anx...cording to research. The study involved 3,621 Unit... a health screening questionnaire within 90 days a...
...group of IT students here have developed a device ... see or read//. Called 'E-Netra', it costs Rs.2,00...tem and converts them into voice that can be heard...es. Right now it can only read text, but later i...
...California-based Keralite doctor has bagged this y...the National Ethnic Coalition of Organisations (NE...e award May 12, said he was "really delighted". "T...be a boost for all my future endeavours," Eapen to...
...e Delhi High Court Wednesday held that the misuse ...taff would be viewed seriously, stressing// that t...vision bench of Justice T.S. Thakur and Justice S....of the hospitals of both state and central governm...
Other Medicine News:Health News:Migraines may Be a Symptom of Other Problems for Iraq Soldiers 2
(Date:5/22/2008)...May 22 /- Roche announced today that ...its oral chemotherapy Xeloda(R),(capecitabine) hav...can,Society of Clinical Oncology (ASCO) Annual Mee...stract to be published in The 2008 ASCO Proceeding...tigational,seven-days-on/seven-days-off (7-on/7-o...
(Date:5/22/2008)...Argentina, May 22 /- On May...), the press conference,entitled, "New Perspective...hn Camm, Professor of Clinical Cardiology, St Geor...nce of the newly announced ATHENA clinical,trial r...illation, a common,form of cardiac arrhythmia., "...
(Date:5/22/2008)...ysis of rEEG(R) Guided Medication Study Demonstrat... Disorder Symptoms, COSTA MESA, Calif., May 22 /P...lletin Board: CNSO) reported today the results of ...ciation (APA) 161st Annual Meeting by Dr.,James Gr...vioral Care,Inpatient Psychiatry and Eating Disord...
(Date:5/21/2008)...core the Utility of CAPHOSOL in Treating Oral Muco...w data show that CAPHOSOL(R), (http://www.caphosol... painful oral,mucositis (OM) and improves quality ...y and radiation therapy. These data were reported ...d Annual Congress of the,Oncology Nursing Society ...
Breaking Medicine Technology:Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting 2Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting 3ATHENA Clinical Results with Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 2ATHENA Clinical Results with Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 3ATHENA Clinical Results with Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 4ATHENA Clinical Results with Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 5ATHENA Clinical Results with Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 6CNS Response, Inc. Provides Review of Poster Session Delivered at the American Psychiatric Association 161st Annual Meeting 2CNS Response, Inc. Provides Review of Poster Session Delivered at the American Psychiatric Association 161st Annual Meeting 3CNS Response, Inc. Provides Review of Poster Session Delivered at the American Psychiatric Association 161st Annual Meeting 4CNS Response, Inc. Provides Review of Poster Session Delivered at the American Psychiatric Association 161st Annual Meeting 5CNS Response, Inc. Provides Review of Poster Session Delivered at the American Psychiatric Association 161st Annual Meeting 6CAPHOSOL(R) Relieves Oral Mucositis (OM) and Improves Quality-of-Life in Cancer Patients Receiving Chemoradiation 2CAPHOSOL(R) Relieves Oral Mucositis (OM) and Improves Quality-of-Life in Cancer Patients Receiving Chemoradiation 3CAPHOSOL(R) Relieves Oral Mucositis (OM) and Improves Quality-of-Life in Cancer Patients Receiving Chemoradiation 4CAPHOSOL(R) Relieves Oral Mucositis (OM) and Improves Quality-of-Life in Cancer Patients Receiving Chemoradiation 5CAPHOSOL(R) Relieves Oral Mucositis (OM) and Improves Quality-of-Life in Cancer Patients Receiving Chemoradiation 6Assay Designs 28TM 29 Announces Additions to the Leadership Team 955 1Assay Designs 28TM 29 Announces Additions to the Leadership Team 955 2Sign Up Now for Project Management Essentials Three Days of Training in IT Project Management Fundamentals 2451 1Sign Up Now for Project Management Essentials Three Days of Training in IT Project Management Fundamentals 2451 2New Website Launches Healthy Vending in Schools Nationwide to Help Combat Childhood Obesity 2446 1New Website Launches Healthy Vending in Schools Nationwide to Help Combat Childhood Obesity 2446 2New Website Launches Healthy Vending in Schools Nationwide to Help Combat Childhood Obesity 2446 3Inaugural Conference AdvaMed 2007 Kicks Off Today 949 1Inaugural Conference AdvaMed 2007 Kicks Off Today 949 2Inaugural Conference AdvaMed 2007 Kicks Off Today 949 3
...- Forest,Laboratories, Inc. and PAION AG today ann... In Acute Ischemic Stroke) study with the,compound...,investigate the improvement of clinical outcome i... Desmoteplase within 3 to 9 hours,after onset of s...,efficacy endpoint (difference between active trea...
... Research,collaborators with Oncolytics Biotech In...r presentation covering REOLYSIN(R),clinical trial...,(ASCO) Annual Meeting, to be held June 1-5, 2007 ...tics, U.K. Phase I systemic,administration trial. ... Study of,Wild-Type Oncolytic Reovirus Administere...
Other Medicine Technology:Topline Results of Phase III Study in Acute Ischemic Stroke,(Dias-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 2Topline Results of Phase III Study in Acute Ischemic Stroke,(Dias-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 3Topline Results of Phase III Study in Acute Ischemic Stroke,(Dias-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 4Oncolytics Biotech Inc.'s Research Collaborators to Present,REOLYSIN Clinical Trial Data at ASCO Conference 2
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
Medicine Products: